PMID- 24059324
OWN - NLM
STAT- MEDLINE
DCOM- 20141205
LR  - 20191027
IS  - 1996-3181 (Electronic)
IS  - 1871-5273 (Linking)
VI  - 13
IP  - 2
DP  - 2014 Mar
TI  - Fighting Alzheimer's disease and type 2 diabetes: pathological links and 
      treatment strategies.
PG  - 271-82
AB  - The incidence of Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) 
      with associated serious complications continues to grow rapidly especially in 
      developed countries. Emerging evidence indicates that AD and T2DM share some 
      common risk factors with comparable pathological features including insulin 
      resistance, amyloidogenesis, glucocorticoid imbalance, inflammation, 
      mitochondrial function and oxidative stress. T2DM has been identified as a risk 
      factor for AD. It has even been hypothesized that AD might be "type 3 diabetes". 
      In addition to amyloid precursor protein processing and tau phosphorylation, 
      commonalities between T2DM and AD in molecular mechanisms provide clues to the 
      identification of novel therapeutic targets such as glucagon-like peptide 1, 
      butyrylcholinesterase, and receptor for advanced glycosylation end products. 
      Although several classes of anti-diabetic drugs are available, achieving 
      long-term glycaemic control without side effects is often challenging. This 
      review summarizes recent evidence for the pathological links, common therapeutic 
      targets, currently the U.S. Food and Drug Administration approved and potential 
      future therapies, giving special attention to ongoing clinical trials of 
      antidiabetic drugs in AD patients and common therapeutic strategies in the 
      management of both AD and T2DM.
FAU - Dai, Ying
AU  - Dai Y
FAU - Kamal, Mohammad A
AU  - Kamal MA
AD  - Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline 
      Avenue, Room CLS- 628, Brookline, MA 02445, USA. ydai@bidmc.harvard.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - CNS Neurol Disord Drug Targets
JT  - CNS & neurological disorders drug targets
JID - 101269155
SB  - IM
MH  - Alzheimer Disease/*drug therapy/*physiopathology
MH  - Animals
MH  - Diabetes Mellitus, Type 2/*drug therapy/*physiopathology
MH  - Humans
EDAT- 2013/09/26 06:00
MHDA- 2014/12/15 06:00
CRDT- 2013/09/25 06:00
PHST- 2012/12/03 00:00 [received]
PHST- 2013/02/17 00:00 [revised]
PHST- 2013/02/19 00:00 [accepted]
PHST- 2013/09/25 06:00 [entrez]
PHST- 2013/09/26 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - CNSNDDT-EPUB-56136 [pii]
AID - 10.2174/18715273113126660134 [doi]
PST - ppublish
SO  - CNS Neurol Disord Drug Targets. 2014 Mar;13(2):271-82. doi: 
      10.2174/18715273113126660134.